Scarica l'app Stockscreener
0.226
3.83%
-0.0118
Jupiter Neurosciences Inc Borsa (JUNS) Ultime notizie
D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering - newswire.com
JUNS Q4 2025 Earnings: Narrower Loss Surprises, Yet Stock Falls on Pre‑Revenue PathPopular Market Picks - Newser
Jupiter Neurosciences (JUNS) Q4 2025 Earnings: EPS Beat Masks Zero-Revenue Reality; Shares Slide 12%Free Signal Network - Newser
What is Driving Jupiter Neurosciences' Recent Stock Volatility - Kavout
A Tiny Psychedelic Stock Just Exploded Over 50% – Retail Traders Think $1 Is Next - Stocktwits
JUNS stock sees best single-day gains in almost a year on $100M MDMA drug licensing deal – retail expects shares to hit $1 - MSN
Jupiter Neurosciences, Inc. Secures $2 Million in Direct Offering to Support Parkinson’s Program and Strengthen Balance Sheet - Quiver Quantitative
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering - marketscreener.com
$2M cash injection backs Jupiter Parkinson’s trial plans - Stock Titan
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
What's going on in today's after hours session - ChartMill
Jupiter Neurosciences (JUNS) priced 7.14M-share direct offering at $0.28 - Stock Titan
The trading volume of these stocks is deviating from the norm in today's session. - ChartMill
Jupiter Neurosciences Announces Registered Direct Equity Offering - TipRanks
Jupiter Neurosciences (NASDAQ: JUNS) files May 21, 2026 prospectus supplement - Stock Titan
Jupiter Neurosciences Prices $2.0 Million Registered Direct Offering at $0.28 Per Share - TradingView
Jupiter Neurosciences (JUNS) raises $2.0M in registered direct stock sale - Stock Titan
Jupiter Neurosciences (JUNS) raises $2.0M via 7.14M-share placement - Stock Titan
Jupiter Neurosciences Stock Swings on $100M MDMA Pact, $2M Equity Sale - TechStock²
Jupiter Neurosciences Secures $100M Term Sheet for U.S. Rights to PharmAla’s MDMA Therapy ALA-002 - The National Law Review
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering - marketscreener.com
Biopharmaceutical Jupiter Neurosciences plans $2M stock sale - Stock Titan
Jupiter stock soars after $100 million ALA-002 licensing deal - MSN
Most active stocks in Wednesday's session - ChartMill
Jupiter Neurosciences Licenses PharmAla Biotech Lead Psychedelic Drug - HarianBasis.co
PharmAla Biotech Signs Term Sheet for $100 Million U.S. Licensing Deal for ALA-002 MDMA Therapy (MDXXF) - Yahoo Finance
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to PharmAla’s Next-Generation MDMA Therapeutic ALA-002 After Landmark Executive Order 1 - Minichart
Jupiter Stock Soars After $100 Million ALA-002 Licensing DealJupiter Neurosciences (NASDAQ:JUNS) - Benzinga
Jupiter Neurosciences (NASDAQ: JUNS) inks term sheet for ALA-002 U.S. rights - Stock Titan
Traders are paying attention to the gapping stocks in Wednesday's session. - ChartMill
Jupiter Neurosciences Pursues MDMA Asset Licensing Deal - TipRanks
Jupiter Neurosciences signs term sheet to acquire U.S. rights to ALA-002 with $3.33M upfront - TradingView
Jupiter Neurosciences (NASDAQ: JUNS) pursues exclusive U.S. rights to ALA-002 - Stock Titan
Jupiter Neurosciences stock surges on MDMA therapy licensing deal By Investing.com - Investing.com South Africa
Jupiter Neurosciences stock surges on MDMA therapy licensing deal - Investing.com
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million - The Manila Times
Stay updated with the stocks that are on the move in today's pre-market session. - ChartMill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Jupiter Neurosciences, Inc. Enters Agreement to Acquire U.S. Rights for ALA-002, Advancing Position in MDMA-Based Therapeutics Amid Regulatory Changes - Quiver Quantitative
After Trump psychedelics order, Jupiter signs $100M MDMA term sheet - Stock Titan
Jupiter Neurosciences (JUNS) Q4 2025 Earnings Beat: Revenue $N/A, EPS $-0.07Pricing Power - Newser
JUNS Stock Price, Quote & Chart | JUPITER NEUROSCIENCES INC (NASDAQ:JUNS) - ChartMill
Jupiter Neurosciences (NASDAQ: JUNS) posts Q1 loss, cites going-concern; SEPA noted - Stock Titan
Jupiter Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Jupiter Neurosciences (JUNS) Q1 2026 loss, Nasdaq warnings and cash burn detailed - Stock Titan
Number of shareholders of Jupiter Neurosciences, Inc. – NASDAQ:JUNS - TradingView
What Jupiter Neurosciences (JUNS) is doing that smart investors recognize (Smart Money Flows) 2026-05-11Breadth Thrust - Newser
Jupiter Neurosciences: Resveratrol for neuroinflammation & CNS diseases - MSN
Jupiter Neurosciences (NASDAQ: JUNS) files 10‑K; Phase IIa IND for Parkinson’s cleared - Stock Titan
Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit - TradingView
Wall Street summit puts Jupiter Neurosciences on the May 5 agenda - Stock Titan
JUNS - Finviz
Top LosersStock ScreenerSnapshot - Finviz
[EFFECT] JUPITER NEUROSCIENCES, INC. SEC Filing - Stock Titan
Is Jupiter Neurosciences (JUNS) stock underpriced in the market | Q4 2025: EPS Beats ForecastsRevenue Report - Newser
JUPITER NEUROSCIENCES INC (JUNS) Fundamental Analysis & Valuation - ChartMill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Jupiter: Rise in AUMs Driven by CCLA Acquisition Completion, Net Inflows - Moomoo
2.25%
0.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):